Non-Chemo Regimen Highly Active in R/R Hodgkin Lymphoma

(MedPage Today) -- Three-fourths of patients with relapsed/refractory Hodgkin lymphoma remained alive without disease progression 3 years after treatment with nivolumab (Opdivo) and brentuximab vedotin (Adcetris), a prospective multicenter trial...